Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ABBV | NYSE | USD | Real-time | |
0QCV | London | EUR | Real-time | |
ABBV | BIVA | MXN | Delayed | |
ABBV | Mexico | MXN | Delayed | |
1ABBV | Milan | EUR | Real-time | |
4AB | TradeGate | EUR | Delayed | |
4AB | Frankfurt | EUR | Delayed | |
ABBV34 | B3 | BRL | Delayed | |
ABBV | Vienna | EUR | Real-time | |
ABBV | Lima | USD | Delayed |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Buy | Buy | Buy | Buy | Buy |
Technical Indicators | BUY | Strong Buy | Strong Buy | Strong Sell | Strong Buy |
Summary | Buy | Strong Buy | Strong Buy | Neutral | Strong Buy |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Belt Hold Bullish | 15 | Current | |||
Bullish Engulfing | 15 | Current | |||
Belt Hold Bullish | 30 | Current | |||
Bullish Engulfing | 30 | Current | |||
Bullish Engulfing | 1H | Current | |||
Completed Patterns | |||||
Engulfing Bearish | 30 | 1 | Apr 25, 2024 20:00 | ||
Tri-Star Bearish | 1D | 2 | Apr 22, 2024 | ||
Engulfing Bearish | 5H | 2 | Apr 24, 2024 18:00 |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
NYSE | 160.88 | 0.00 | 0.00 | 3,073,433 | -3.83% | USD | 16:04:06 | ||
London | 160.88 | 155.30 | 169.04 | 1,390 | -3.54% | EUR | |||
BIVA | 2,880.00 | 0.00 | 0.00 | 0 | 0.00% | MXN | |||
Mexico | 2,880.00 | 0.00 | 0.00 | 0 | +0.00% | MXN | |||
Milan | 156.44 | 0.00 | 0.00 | 263 | +1.20% | EUR | |||
TradeGate | 151.10 | 151.02 | 151.40 | 3,721 | -2.67% | EUR | |||
Frankfurt | 152.82 | 151.02 | 151.50 | 53 | -3.06% | EUR | |||
B3 | 52.00 | 51.75 | 52.10 | 104 | -3.17% | BRL | |||
Vienna | 164.70 | 161.00 | 164.70 | 0 | +0.00% | EUR | |||
Lima | 168.80 | 0.00 | 0.00 | 0 | 0.00% | USD |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
Barclays | 204.05 | 204.85 | 199.08 | +0.05 | +0.03% | 37.09M | 16:04:18 | ||
AstraZeneca | 11,966.0 | 12,144.0 | 11,882.0 | -60.0 | -0.50% | 1.04M | 16:04:09 | ||
Legal & General | 234.85 | 236.69 | 234.18 | +2.05 | +0.88% | 12.47M | 16:04:10 | ||
Rolls-Royce Holdings | 420.30 | 420.40 | 409.20 | +14.60 | +3.60% | 14.47M | |||
Anglo American | 2,643.5 | 2,721.0 | 2,518.5 | +83.5 | +3.26% | 8.34M | 16:04:15 | ||
Lloyds Banking | 52.28 | 52.60 | 51.08 | +1.08 | +2.11% | 94.14M | |||
IAG | 176.85 | 179.00 | 176.72 | +0.70 | +0.40% | 6.68M | |||
NatWest Group | 307.18 | 308.70 | 295.50 | +17.38 | +6.00% | 26.03M | 16:04:03 | ||
HSBC | 663.30 | 665.80 | 661.10 | +1.40 | +0.21% | 6.10M | |||
BAE Systems | 1,342.50 | 1,343.50 | 1,307.00 | +22.50 | +1.71% | 3.65M |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review